Theralase Technologies Inc. V.TLT

Today's Announcement

[99942Apophis]

Discussion today seemed confused even though it was clearly pointed out how the funds will be used. If the company wishes to initiate the following before BTD & AA are awarded they will need capital to proceed. True a JV would be desirable a strong position of achievements on their own would demand a better deal for this company in such an arrangement. I see here a small company about to grow in size and strength, I am happy with what is about to unfold, cheers.

The Company intends to use the proceeds of the Financing for the following:

• Good Laboratory Practice (“GLP”) toxicology study for intravenous installation of Rutherrin® intended for the treatment of Non-Small Lung Cancer (“NSCLC”) and Glio-Blastoma Multiforme (“GBM”), a fast-growing and aggressive brain tumor.
• Advancement of Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study
• Working capital and general corporate purposes

[BlueFranky]

Thanks Apophis... Precisely my take as well

[consultant99]

It remains to be seen how much money will actually be spent between now and say Q1 of 2023 for NSCLC and GBM development.  As far as the completion of the Phase 2 Bladder cancer trial it was my understanding the company had sufficient funds to complete the trial as per management notes. Due to the Covid related delays I assumed that meant there were sufficient funds to get through the first

[Rumpl3StiltSkin]

I think that is correct 99, I don't know exactly what the $$ will be used for. But I think they will focus on the GLP and new Phase 1s. and new NMIBC patients that come into the Phase 2 trial.  Before too long we should be a multiple indication cancer stock :-) IF Covid vaxx happens it should be PHAC that takes care of future funding for that. Includig a nice check going to TLT.